What are Ovid Therapeutics Inc's Business Segments?
Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing medical treatments for rare neurological diseases. The company offers a range of products and services in the field of neuroscience.
Segments:
1. Drug Development: Ovid Therapeutics Inc. develops drugs to treat rare neurological disorders such as Angelman syndrome, Fragile X syndrome, and CDKL5 deficiency disorder. Their portfolio includes OV329, OV882, and OV101.
2. Research and Development: The company invests significantly in researching innovative methods for treating rare neurological diseases. Their R&D programs are aimed at exploring new drug targets and developing new therapies.
Products:
1. OV101 (gaboxadol): OV101 is a small molecule drug that is being developed as a potential treatment for Angelman syndrome, a rare genetic disorder that causes developmental disabilities and seizures. OV101 works by targeting the GABA-A receptor, which modulates the activity of the brain's inhibitory neurons.
2. OV329: OV329 is a small molecule drug that is being developed as a potential treatment for Fragile X syndrome, a genetic disorder that causes intellectual disability and behavioral problems. OV329 works by targeting the mGluR5 receptor, which regulates the activity of glutamate, a key neurotransmitter in the brain.
3. OV882: OV882 is a small molecule drug that is being developed as a potential treatment for CDKL5 deficiency disorder, a rare genetic disorder that causes developmental delays, seizures, and other neurological problems. OV882 works by targeting the mitogen-activated protein kinase (MAPK) pathway, which is involved in neuronal signaling.
Services:
1. Clinical Trials: Ovid Therapeutics Inc. conducts clinical trials to evaluate the safety and efficacy of their drugs. The company collaborates with leading academic institutions and clinical research organizations to conduct these trials.
2. Patient Support Programs: Ovid Therapeutics Inc. provides patient support programs to assist patients and their families in accessing their drugs. These programs include educational materials, financial assistance, and access to clinical trials.
3. Scientific Collaboration: The company collaborates with leading academic institutions and research organizations to advance the scientific understanding of rare neurological diseases. Ovid Therapeutics Inc. works with these partners to develop new therapies and improve patient outcomes.
|